SWTX Stock Cash Flow Statements

SpringWorks Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

SpringWorks Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31

operating activities
net income	-83,187,000	-77,297,000	-53,530,000	-39,919,000	-87,385,000	-94,322,000	-79,437,000	-77,925,000	-73,420,000	-74,178,000	-72,388,000	-69,050,000	-61,801,000	-56,072,000	-41,041,000	-47,010,000	-29,787,000	11,272,000	-21,659,000	-19,893,000	-15,294,000	-16,217,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization expense	1,101,000	1,017,000	878,000	844,000	729,000
non-cash operating lease expense	525,000	262,000	680,000	443,000	400,000	477,000	439,000	451,000	286,000	286,000	286,000	287,000	272,000	248,000	243,000	245,000	257,000
equity-based compensation expense	29,948,000	26,470,000	25,963,000	26,245,000	30,462,000
equity method investment loss and impairment	6,595,000
changes in operating assets and liabilities
accounts receivable	5,891,000	-13,266,000	-8,468,000	-8,975,000	-9,599,000
inventory	-2,205,000	-386,000	-2,108,000	-2,502,000	-2,113,000
prepaid expenses and other current assets	347,000	-336,000	-477,000	-747,000	-1,793,000	-2,713,000	-2,770,000	2,322,000	-1,968,000	-2,204,000	2,114,000	222,000	1,729,000	-4,308,000	-887,000	-111,000	697,000	-2,831,000	480,000	4,000	1,142,000	-3,020,000
other assets	-656,000	-5,917,000	-461,000	-759,000	-78,000	-152,000	-478,000	35,000	-243,000	-195,000	234,000	-60,000	82,000	-258,000	-232,000	328,000	-545,000	-562,000	0	0	-281,000	363,000
accounts payable	2,861,000	2,664,000	1,580,000	745,000	-385,000	2,065,000	2,574,000	-4,082,000	-753,000	3,006,000	2,395,000	537,000	-1,770,000	926,000	-1,406,000	1,675,000	879,000	286,000	155,000	-708,000	-1,037,000	497,000
accrued expenses	-29,336,000	36,112,000	9,248,000	1,097,000	-9,625,000	13,963,000	5,012,000	7,186,000	-10,255,000	-217,000	8,104,000	10,133,000	-4,695,000	1,299,000	5,638,000	2,618,000	357,000	3,626,000	3,007,000	1,670,000	-2,358,000	1,271,000
lease liability	-643,000	-17,995,000	-493,000	-491,000	-568,000	-430,000	-417,000	-55,000	-391,000	-558,000	-111,000	-146,000	-44,000	-349,000	-342,000	-342,000	-355,000
net cash from operating activities	-68,759,000	-29,500,000	-25,379,000	-41,790,000	-78,930,000	-62,705,000	-50,461,000	-47,811,000	-61,818,000	-54,200,000	-19,604,000	-39,071,000	-48,688,000	-46,316,000	-26,929,000	-33,528,000	-21,104,000	15,066,000	-14,700,000	-16,159,000	-16,398,000	-16,063,000
investing activities
capital expenditures	-30,000	-1,052,000	-1,847,000	-975,000	-577,000	2,302,000	-3,622,000	-3,088,000	-2,977,000	-1,756,000	-3,528,000	-2,525,000	-2,387,000	-1,504,000	-335,000	-132,000	-45,000	-54,000	-167,000	-261,000	-160,000
free cash flows	-68,789,000	-30,552,000	-27,226,000	-42,765,000	-79,507,000	-60,403,000	-54,083,000	-50,899,000	-64,795,000	-55,956,000	-23,132,000	-41,596,000	-51,075,000	-47,820,000	-27,264,000	-33,660,000	-21,149,000	15,012,000	-14,867,000	-16,420,000	-16,558,000
equity method investment		0	0	0	-8,235,000
purchases of marketable securities		-80,844,000	-45,025,000	-85,590,000	-73,642,000	-266,448,000	-96,664,000	-144,464,000	-68,148,000	-413,097,000	0	-44,711,000	-23,242,000	-86,560,000	-77,966,000	-54,524,000	-86,373,000	-250,727,000	-127,396,000
proceeds from sale and maturity of marketable securities	73,423,000	101,041,000	75,520,000	98,104,000	103,917,000
net cash from investing activities	73,393,000	14,145,000	28,648,000	289,000	21,463,000	-159,205,000	34,599,000	60,756,000	98,604,000	-355,010,000	86,232,000	26,757,000	26,424,000	56,181,000	35,785,000	22,544,000	-30,918,000	-222,781,000	-127,563,000	-68,328,000	-160,000	-130,000
financing activities
treasury stock	-12,869,000	-523,000	-499,000	-919,000	-6,497,000	-253,000	-264,000	-352,000	-1,931,000	0	-212,000
proceeds from stock option exercises	2,260,000	1,176,000	1,790,000	4,290,000	5,945,000	24,000	22,000	10,000	83,000	298,000	377,000	135,000	1,167,000	244,000	425,000	129,000	359,000	381,000	428,000	78,000	6,000	20,000
net cash from financing activities	-10,609,000	653,000	1,291,000	3,371,000	-552,000	299,071,000	-242,000	-342,000	-1,848,000	298,000	340,231,000	-88,000	261,000	244,000	425,000	129,000	359,000	269,973,000	428,000	78,000	6,000	20,000
net increase in cash and cash equivalents	-5,975,000	-14,702,000	4,560,000	-38,130,000	-58,019,000	77,161,000	-16,104,000	12,603,000	34,938,000							-10,855,000	-51,663,000	62,258,000	-141,835,000	-84,409,000	-16,552,000	-16,173,000
cash and cash equivalents including restricted cash, beginning of period	70,375,000	0	0	0	176,666,000	0	0	0	68,068,000	0	0	0	104,526,000	0	0	0	147,654,000	0	0	0	328,192,000
cash and cash equivalents including restricted cash, end of period	64,400,000	-14,702,000	4,560,000	-38,130,000	118,647,000	77,161,000	-16,104,000	12,603,000	103,006,000	-408,912,000	406,859,000	-12,402,000	82,523,000	10,109,000	9,281,000	-10,855,000	95,991,000	62,258,000	-141,835,000	-84,409,000	311,640,000
supplemental non-cash disclosure
milestone payment for first commercial sale of gomekli included in accrued expenses as of march 31, 2025	6,000,000
equity method investment loss		1,390,000	1,809,000	1,776,000	1,025,000
deferred revenue		17,782,000	0
payment for intangible asset		-5,000,000	0
proceeds from issuance of common stock in underwritten public offering, net of issuance costs
proceeds from issuance of common stock to gsk										0
proceeds from issuance of common stock in private placement, net of issuance costs										0
proceeds from issuance of common stock under at-the-market offering, net of issuance costs										0
right-of-use assets obtained in exchange for operating lease obligations		0	0			0	0			0	0
milestone payment for first commercial sale of ogsiveo included in accrued expenses as of december 31, 2023
non-cash investing activities
other liabilities
depreciation expense							494,000	382,000	253,000	255,000	212,000	190,000	108,000	146,000	119,000	115,000	110,000	110,000	95,000	74,000	70,000	65,000
stock compensation expense							23,098,000	22,974,000	23,395,000	18,924,000	18,518,000	18,429,000	17,094,000	11,882,000	10,712,000	8,795,000	7,055,000	3,042,000	3,043,000	2,599,000	1,350,000	950,000
equity investment loss							1,024,000	901,000	1,278,000	680,000	1,486,000	387,000	337,000	301,000	267,000	159,000	261,000	146,000	130,000	229,000	100,000	113,000
equity investments							0			0	0							0	0
proceeds from sale and maturity of debt securities							134,885,000	208,308,000	172,529,000	59,843,000	89,760,000	78,193,000	52,053,000	144,245,000	114,086,000	77,200,000	55,500,000
equity investment									-2,800,000
proceeds from issuance of common stock upon closing of follow-on offering, net of issuance costs
net decrease in cash and cash equivalents												-12,402,000	-22,003,000
supplemental non-cash items not included above resulting from the adoption of asc 842
initial recognition of operating lease right of use asset
initial recognition of lease liabilities
other long-term liabilities														-131,000	0	0	-33,000	68,000
shares of common stock repurchased to satisfy tax withholding obligations													-906,000
deferred rent																			-91,000	-90,000	-90,000	-85,000
proceeds from issuance of common stock, net of issuance costs																						0
proceeds from issuance of series a convertible preferred shares, net of issuance costs																						0
proceeds from issuance of series b convertible preferred shares, net of issuance costs																						0
other

unrealized loss on marketable securities
non-cash license expense
purchases of property and equipment
investment in mapkure
cash and cash equivalents, beginning of period
cash and cash equivalents, end of period

We provide you with 20 years of cash flow statements for SpringWorks Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SpringWorks Therapeutics stock. Explore the full financial landscape of SpringWorks Therapeutics stock with our expertly curated income statements.

The information provided in this report about SpringWorks Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.